Table 2.
Recent and ongoing HIV-1 clinical trials.
| Name | Year Started and Country/Continent | Phase | Molecular Basis of Vaccine | Efficacy/Response or Completion Date | Relevant Comments | NCT Number or Author |
|---|---|---|---|---|---|---|
| HVTN 702 | 2016, South Africa | 2b/3 | ALVAC-HIV and subtype C gp120/MF59 | No efficacy | NCT02968849 | |
| Antibody-Mediated Protection, HVTN 703 | 2016, sub-Saharan Africa | 2b | VRC01 broadly neutralizing monoclonal antibody infusion | Did not prevent HIV-1 acquisition | Similar to HVTN 704 but clinical participants were women | NCT02568215 |
| Antibody-Mediated Protection, HVTN 704 | 2016, Brazil, Peru, Switzerland, USA | 2b | VRC01 broadly neutralizing monoclonal antibody infusion | Did not prevent HIV-1 acquisition | Similar to HVTN 703, but clinical participants were men who have sex with men and transgender women | NCT02716675 |
| IAVI A003/CHOP HVDDT 001 | 2014, United Kingdom | 1 | rAAV1-PG9DP | Safe and tolerable, but antibody levels not detected in all participants | NCT01937455 | |
| APPROACH | 2015, east Africa, South Africa, Thailand, and USA | ½ | Ad26.Mos.HIV and Clade C gp140 or MVA mosaic vaccine with gp140 | Safe and tolerable, efficacy will be assessed with HVTN 705 | NCT02315703 | |
| Imbokodo, HVTN 705 | 2017, sub-Saharan Affrica | 2b | Ad26.Mos4.HIV and adjuvanted clade C gp140 and Mosaic gp140 protein | Completion date in 2022 | NCT03060629 | |
| HVTN 706 | 2019, Europe, North, and South America | 3 | Ad26.Mos4.HIV and adjuvanted clade C gp140 and Mosaic gp140 protein | Completion date in 2022 | ||
| CR108152 | 2016, USA and Rwanda | ½ | Ad26.Mos.HIV or Ad26.Mos4.HIV and clade C gp140 plus adjuvant | Completion date in 2023 | NCT02788045 | |
| HIV-CORE 004 | 2014, Kenya | ½ | pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN | Safe and tolerable, all participants had HIVcons specific T cell responses | NCT02099994 | |
| HIV-CORE 0052 | 2021, United Kingdom | 1 | ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 (M3), or MVA.tHIVconsv4 (M4) | Completion date in 2022 | NCT04586673 | |
| PrepVacc | 2020, Mozambique; South Africa; Tanzania; and Uganda | 2b | DNA-HIV-PT123 and AIDSVAX or 2 injections of CN54gp140 + MPLAL and MVA | Completion date in 2023 | All participants on PREP | NCT04066881 |
| IAVI G001 | 2018, USA | 1 | eOD-GT8 60mer + AS01B/DPBS sucrose/IM | Results have not been published in peer reviewed journal | NCT03547245 | |
| IAVI G002 | Estimated start date 2021, USA | 1 | Core-g28v2 60mer mRNA and eOD-GT8 60mer mRNA Vaccine | Completion date in 2023 | NCT05001373 |